PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives

Advanced, recurrent and metastatic endometrial cancer (EC) has a dismal prognosis due to poor response rates to conventional treatments. In the era of precision medicine, the improved understanding of cancer genetics and molecular biology has led to the development of targeted therapies, such as pol...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Manag Res
Autors principals: Musacchio, Lucia, Caruso, Giuseppe, Pisano, Carmela, Cecere, Sabrina Chiara, Di Napoli, Marilena, Attademo, Laura, Tambaro, Rosa, Russo, Daniela, Califano, Daniela, Palaia, Innocenza, Muzii, Ludovico, Benedetti Panici, Pierluigi, Pignata, Sandro
Format: Artigo
Idioma:Inglês
Publicat: Dove 2020
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7383016/
https://ncbi.nlm.nih.gov/pubmed/32801862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S221001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars